0.03 (7.5%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.6558.0886
Address
Level 3 101 St George’s Terrace Perth, Western Australia (WA) 6000
Description
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.28 - 1.09
Trade Value (12mth)
AU$753.00
1 week
5.26%
1 month
-14.89%
YTD
-35.48%
1 year
-42.45%
All time high
20453.10
EPS 3 yr Growth
150.20%
EBITDA Margin
%
Operating Cashflow
-$4m
Free Cash Flow Return
-31.60%
ROIC
-263.70%
Interest Coverage
-7.70
Quick Ratio
0.40
Shares on Issue (Fully Dilluted)
11m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
29 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
28 April 25 |
Full Conversion of $USD3.25M Convertible Notes in HOPE SPV
×
Full Conversion of $USD3.25M Convertible Notes in HOPE SPV |
|
03 April 25 |
Investor Presentation
×
Investor Presentation |
|
01 April 25 |
Application for quotation of securities - ZLD
×
Application for quotation of securities - ZLD |
|
31 March 25 |
Zelira secures $1 Million At-the-Market Funding Facility
×
Zelira secures $1 Million At-the-Market Funding Facility |
|
31 March 25 |
Proposed issue of securities - ZLD
×
Proposed issue of securities - ZLD |
|
31 March 25 |
Cleansing Prospectus
×
Cleansing Prospectus |
|
26 February 25 |
Appendix 4D & FY25 Interim Financial Report
×
Appendix 4D & FY25 Interim Financial Report |
|
18 February 25 |
Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
×
Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund |
|
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
28 January 25 |
Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
×
Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche |
|
20 January 25 |
Change of Director's Interest Notice x 2
×
Change of Director's Interest Notice x 2 |
|
17 January 25 |
Notification of cessation of securities - ZLD
×
Notification of cessation of securities - ZLD |
|
19 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
|
18 December 24 |
Notification regarding unquoted securities - ZLD
×
Notification regarding unquoted securities - ZLD |
|
20 November 24 |
Zelira to present at Automic Invest 2024 conference
×
Zelira to present at Automic Invest 2024 conference |
|
14 November 24 |
2024 Annual General Meeting Presentation
×
2024 Annual General Meeting Presentation |
|
14 November 24 |
Results of Meeting
×
Results of Meeting |
|
14 November 24 |
Proposed issue of securities - ZLD
×
Proposed issue of securities - ZLD |
|
29 October 24 |
September 2024 Quarterly Activities Report
×
September 2024 Quarterly Activities Report |
|
29 October 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
|
11 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
|
11 October 24 |
Letter to Shareholders
×
Letter to Shareholders |
|
20 September 24 |
Investor Webinar - HOPE FDA Program Update
×
Investor Webinar - HOPE FDA Program Update |
|
18 September 24 |
Notice of Investor Webinar - HOPE FDA Program Update
×
Notice of Investor Webinar - HOPE FDA Program Update |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
